Recent Finacing
Recent Raise
Polyneuron develops injectable biodegradable high‑molecular‑weight glycopolymers (Antibody‑Catch) that bind and remove pathogenic autoantibodies; lead candidate PN‑1007 is advancing to clinical trials for anti‑MAG neuropathy.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
